INNOVA CAPTAB LIMITED (NSE: INNOVACAP, BSE: 544067) is a Panchkula, Haryana-based company in the Domestic contract manufacturers industry. With a market capitalisation of ₹6,249 Cr, it ranks #761 by market cap among the 6,197 Indian listed companies on FinBizNet, and #2 of 4 in Domestic contract manufacturers. At ₹1,002.00 (as of 19 Nov 2026), the share price is 26.0% below its 52-week high of ₹1,353.50 and 61.1% above its 52-week low of ₹622.00. The share price is up 37.2% over one year and down 3.6% over three months.
| Current Price | ₹1,002.00 |
|---|---|
| Market Cap | ₹6,249 Cr |
| NSE Symbol | INNOVACAP |
| BSE Code | 544067 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Domestic contract manufacturers |
| P/E Ratio | 47.3 |
| Return on Equity | 14.03% |
| Return on Assets | 6.83% |
| 52-Week Range | ₹622.00 – ₹1,353.50 |
| 1-Year Price Change | +37.2% |
| 3-Month Price Change | -3.6% |
| Beta (1Y) | 0.5 |
| Dividend Yield | 0.34% |
| Headquarters | Panchkula, Haryana |
| Website | innovacaptab.com |
| Revenue | ₹496 Cr |
|---|---|
| Net Profit | ₹42 Cr |
| Net Margin | 8.5% |
| EPS (Basic) | ₹7.41 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
INNOVA CAPTAB LIMITED reported revenue of ₹496 Cr in Q2 FY27, up 30.5% from ₹380 Cr in Q2 FY26 and up 5.4% from ₹471 Cr in Q1 FY27. It posted a net profit of ₹42 Cr for the quarter, against a net profit of ₹30 Cr in Q2 FY26 (up 43.0%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹315 Cr (Q4 FY25) to ₹496 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹496 Cr | ₹42 Cr | 8.5% |
| Q1 FY27 | ₹471 Cr | ₹44 Cr | 9.4% |
| Q4 FY26 | ₹448 Cr | ₹40 Cr | 9.0% |
| Q3 FY26 | ₹450 Cr | ₹42 Cr | 9.4% |
| Q2 FY26 | ₹380 Cr | ₹30 Cr | 7.8% |
| Q1 FY26 | ₹352 Cr | ₹31 Cr | 8.8% |
| Q4 FY25 | ₹315 Cr | ₹30 Cr | 9.4% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 50.90% of INNOVA CAPTAB LIMITED's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 45.7% of traded volume across 18 NSE sessions (26 Oct 2026 – 19 Nov 2026).
Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder inject
1. Drugs and Pharmaceutical Products-This segment engages in the manufacturing and trading of drugs and pharmaceuticals. 2. NA-NA 3. NA-NA 4. NA-NA
1. Drugs and Pharmaceutical Products-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Akums Drugs and Pharmaceuticals Limited | ₹11,787 Cr | 45 | 8.02% | ₹1,342 Cr | +57.3% |
| INNOVA CAPTAB LIMITED | ₹6,249 Cr | 47.3 | 14.03% | ₹496 Cr | +37.2% |
| Windlas Biotech Ltd | ₹2,060 Cr | 32.6 | 12.23% | ₹264 Cr | +18.9% |
| Influx Healthtech Limited | ₹588 Cr | 28.7 | 20.39% | — | — |
Listed by market capitalisation. Ratios are shown for context only.
INNOVA CAPTAB LIMITED is trading at ₹1,002.00, with a market capitalisation of ₹6,249 Cr.
INNOVA CAPTAB LIMITED operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Domestic contract manufacturers).
INNOVA CAPTAB LIMITED has a P/E of 47.3 and a return on equity of 14.03%.
INNOVA CAPTAB LIMITED is listed on the NSE under the symbol INNOVACAP and on the BSE under the scrip code 544067.
INNOVA CAPTAB LIMITED's share price is up 37.2% over one year and down 3.6% over three months. Its 52-week range is ₹622.00 to ₹1,353.50.
In Q2 FY27, INNOVA CAPTAB LIMITED reported revenue of ₹496 Cr and net profit of ₹42 Cr, with basic EPS of ₹7.41 (consolidated, parsed from the company's exchange filing).
INNOVA CAPTAB LIMITED reported revenue of ₹496 Cr in Q2 FY27, up 30.5% from ₹380 Cr in Q2 FY26 and up 5.4% from ₹471 Cr in Q1 FY27.
Promoters held 50.90% of INNOVA CAPTAB LIMITED's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 19 Nov 2026. Descriptive market data only — not investment advice.